AMAndrew L. Mellor

Andrew L. Mellor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrew L. Mellor has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Ido expression by dendritic cells: tolerance and tryptophan catabolism

    by Andrew L. Mellor, David H. Munn

    Indoleamine 2,3-dioxygenase (IDO) is an enzyme that degrades the essential amino acid tryptophan. The concept that cells expressing IDO can suppress T-cell responses and promote tolerance is a relatively new paradigm in immunology. Considerable evidence now supports this hypothesis, including studies of mammalian pregnancy, tumour resistance, chronic infections and autoimmune diseases. In this review, we summarize key recent developments and propose a unifying model for the role of IDO in tolerance induction.


  • Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion

    by Andrew L. Mellor, Babak Baban, Phillip Chandler, Brendan Marshall, Kanchan Jhaver, Anna Hansen, Pandelakis A Koni, Makio Iwashima, David H. Munn

    In mice, immunoregulatory APCs express the dendritic cell (DC) marker CD11c, and one or more distinctive markers (CD8α, B220, DX5). In this study, we show that expression of the tryptophan-degrading enzyme indoleamine 2,3 dioxygenase (IDO) is selectively induced in specific splenic DC subsets when mice were exposed to the synthetic immunomodulatory reagent CTLA4-Ig. CTLA4-Ig did not induce IDO expression in macrophages or lymphoid cells. Induction of IDO completely blocked clonal expansion of T cells from TCR transgenic mice following adoptive transfer, whereas CTLA4-Ig treatment did not block T cell clonal expansion in IDO-deficient recipients. Thus, IDO expression is an inducible feature of specific subsets of DCs, and provides a potential mechanistic explanation for their T cell regulatory properties.


  • Open Access

    Tryptophan Catabolism and Regulation of Adaptive Immunity

    by Andrew L. Mellor, David H. Munn

    Progress in elucidating cellular, molecular, and biochemical processes that regulate immune responses provides increasingly plausible explanations for the normal status of tolerance to self Ags that guards most humans from Ehrlich’s imagined horror autotoxicus (1). Emerging data on regulatory T cells (Tregs)2 and regulatory APC (APCregs) provide fertile ground for resolving some perplexing immunological paradoxes. (2, 3, 4). Thus, most people harbor potentially autoreactive T and B cells without suffering autoimmune diseases. This situation is reminiscent of the paradox of pathogen and tumor persistence in immunocompetent hosts. Unresponsiveness in these situations is puzzling, raising hopes that immunotherapeutic interventions might reverse tolerance. Tregs and APCregs may be the culprits in these cases, perhaps exploited by mechanisms evolved by pathogens, or acquired by tumors, to protect them from host immunity. Tumor survival and pathogen persistence in immunocompetent hosts has a counterpart in mammalian reproduction. Fetal tissues that express paternally inherited genes (foreign to the mother) are tolerated by the maternal immune system despite intimate association between maternal and fetal tissues during gestation. Recent reviews on Tregs and APCregs (cited above) provide excellent summaries of progress to elucidate their roles in immunoregulatory processes. However, molecular mechanisms underlying immunoregulatory phenomena remain elusive.


  • Tryptophan Catabolism and T Cell Responses

    by Andrew L. Mellor, David Munn, Phillip Chandler, Derin Keskin, Theodore Johnson, Brendan Marshall, Kanchan Jhaver, Babak Baban

    Cells expressing indoleamine 2,3 dioxygenase (IDO) play key roles in regulating adaptive immune responses orchestrated by T cells. In this report we discuss our working model, the tryptophan depletion hypothesis, to explain links between IDO expression and inhibition of T cell responses. We posit that IDO+ cells, particularly professional antigen presenting cells (APCs) promote T cell entry but block cell cycle progression due to tryptophan catabolism. We discuss experimental evidence supporting predictions from the tryptophan depletion hypothesis and the implications that this model has for understanding the origin of tolerant states that explain immunological paradoxes, such as fetal survival, tumor persistence and failure to eradicate pathogens like HIV that cause persistent infections.


  • Open Access

    Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division

    by Geon Kook Lee, Hyeon Jin Park, Megan Macleod, Phillip Chandler, David H. Munn, Andrew L. Mellor

    Summary: Cells expressing indoleamine 2,3‐dioxygenase (IDO), an enzyme which catabolizes tryptophan, prevent T‐cell proliferation in vitro, suppress maternal antifetal immunity during pregnancy and inhibit T‐cell‐mediated responses to tumour‐associated antigens. To examine the mechanistic basis of these phenomena we activated naïve murine T cells in chemically defined tryptophan‐free media. Under these conditions T cells expressed CD25 and CD69 and progressed through the first 12 hr of G0/G1 phase but did not express CD71, cyclin D3, cdk4, begin DNA synthesis, or differentiate into cytotoxic effector cells. In addition, activated T cells with their growth arrested by tryptophan deprivation exhibited enhanced tendencies to die via apoptosis when exposed to anti‐Fas antibodies. Apoptosis was inhibited by caspase inhibitor and was not observed when T cells originated from Fas‐deficient mice. These findings suggest that T cells activated in the absence of free tryptophan entered the cell cycle but cell cycle progression ceased in mid‐G1 phase and T cells became susceptible to death via apoptosis, in part though Fas‐mediated signalling. Thus, mature antigen‐presenting cells expressing IDO and Fas‐ligand may induce antigen‐specific T‐cell tolerance by blocking T‐cell cycle progression and by rapid induction of T‐cell activation induced cell death in local tissue microenvironments.


  • Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy

    by Andrew L Mellor, Phillip Chandler, Geon Kook Lee, Theodore Johnson, Derin B Keskin, Jeffrey Lee, David H Munn


  • Cells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell Responses

    by Andrew L. Mellor, Derin B. Keskin, Theodore Johnson, Phillip Chandler, David H. Munn

    Pharmacological inhibition of indoleamine 2,3-dioxygenase (IDO) activity during murine gestation results in fetal allograft rejection and blocks the ability of murine CD8+ dendritic cells to suppress delayed-type hypersensitivity responses to tumor-associated peptide Ags. These observations suggest that cells expressing IDO inhibit T cell responses in vivo. To directly evaluate the hypothesis that cells expressing IDO inhibit T cell responses, we prepared IDO-transfected cell lines and transgenic mice overexpressing IDO and assessed allogeneic T cell responses in vitro and in vivo. T cells cocultured with IDO-transfected cells did not proliferate but expressed activation markers. The potency of allogeneic T cell responses was reduced significantly when mice were preimmunized with IDO-transfected cells. In addition, adoptive transfer of alloreactive donor T cells yielded reduced numbers of donor T cells when injected into IDO-transgenic recipient mice. These outcomes suggest that genetically enhanced IDO activity inhibited T cell proliferation in vitro and in vivo. Genetic manipulation of IDO activity may be of therapeutic utility in suppressing undesirable T cell responses.


  • Top Cited Papers

    Prevention of T cell–driven complement activation and inflammation by tryptophan catabolism during pregnancy

    by Andrew L. Mellor, Jayabalan Sivakumar, Phillip Chandler, Kimberly Smith, Hector Molina, Dailing Mao, David H. Munn

    Indoleamine 2,3 dioxygenase (IDO) activity during pregnancy protects developing fetuses from maternal immune responses in CBA mice. We show here that fetal allografts were rejected only in mating combinations where paternally inherited tissue antigens elicited potent maternal T cell responses after exposure to IDO inhibitor. IDO inhibitor treatment triggered extensive inflammation at the maternal-fetal interface in susceptible mating combinations, which was characterized by complement deposition and hemorrhagic necrosis. Identical inflammatory responses occurred in B cell–deficient (RAG-1−/− ) mothers that carried a monoclonal cohort of CD8+ T cells specific for a single paternally inherited fetal major histocompatibility complex antigen. Thus, fetal allograft rejection was accompanied by a unique form of inflammation that was characterized by T cell–dependent, antibody-independent activation of complement. In contrast, no inflammation, complement deposition or T cell infiltration was elicited when mice carrying syngeneic fetuses were exposed to IDO inhibitor. These data show that IDO activity protects the fetus by suppressing T cell–driven local inflammatory responses to fetal alloantigens.